SANTA MONICA, Calif., August 05, 2021 (GLOBE NEWSWIRE) – BonRx (NASDAQ: GDRX), America’s leading health savings resource, today announced it has entered into an agreement with Overwritten, the leading national health information network, to provide drug price information to prescribers using Surescripts Real-Time Prescription Benefit when prescribing drugs for uninsured patients and patients with pricing information is not already available in their PBM or health plan. Surescripts Real-Time Prescription Benefit provides cost information in the electronic workflow so prescribers can make more informed decisions and resolve patient prescribing cost issues at the point of care.
About a third of Americans say they forgot to fill a prescription for a chronic condition one or more times because of the cost, according to an internal GoodRx study. investigation. By improving price transparency at the point of care, prescribers can have more informed conversations with their patients and ensure they can afford the treatment they need before going to the pharmacy counter. With this new integration, prescribers using the Surescripts real-time prescribing service will be able to provide uninsured patients and patients whose pricing information is not already available from their PBM or health plan with a GoodRx drug price discount, saving up to 80% off pharmacy retail prices on prescriptions, so patients can make more informed decisions about their care.
“We’re always looking for ways to increase prescription pricing transparency and accessibility for more Americans, so we’re excited to work with Surescripts to provide prescribers with the tools and information they need to choose drugs that are both accessible and clinically appropriate, ”said Doug Hirsch, co-CEO and co-founder of GoodRx.
Surescripts is a nationwide network that connects virtually all electronic health records (EHR) software vendors, pharmacies, and healthcare systems, allowing providers to view patient-specific benefit and cost information, and then prescribe. electronically a drug. Last year, nearly 2 billion electronic prescriptions were dispensed via Surescripts. The integration of GoodRx pricing will put cost information in the hands of patients.
“Point-of-care prescription price transparency is key to improving treatment adherence and ensuring patients can get the treatment they need,” said Mike Pritts, product manager at Surescripts. “With the addition of our drug price reduction feature for uninsured patients as well as for patients whose pricing information is not already available from their PBM or health plan, Real-Time Prescription Benefit gives prescribers more information they need, so they can have meaningful conversations about costs and introduce patients to medications they can access and afford.
To learn more about GoodRx, visit goodrx.com.
GoodRx helps Americans get the health care they need at an affordable price. As America’s premier resource for healthcare savings, GoodRx connects consumers with affordable and convenient prescriptions and medical care, including telehealth, mail order prescriptions, doctor visits and laboratory tests. We’ve helped Americans save over $ 30 billion since 2011 and are one of the most downloaded medical apps over the past decade.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to historical facts should be considered as forward-looking statements, including, but not limited to, statements regarding consumer savings, the availability and use of GoodRx pricing in the Surescripts product and the benefits and use of GoodRx pricing by Surescripts providers and patients. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from future results, performance or achievements. expressed or implied by forward-looking statements. statements, including, but not limited to, risks related to our acquisition strategy, integration of acquired businesses and material factors discussed under “Risk Factors” in GoodRx’s Annual Report on Form 10 -K for the fiscal year ended December 31, 2020, and our other documents filed with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements contained in this press release. These forward-looking statements represent management’s estimates as of the date of this press release. While we may choose to update these forward-looking statements at some time in the future, we disclaim any obligation to do so, even if subsequent events cause our view to change.